Galectin 3 contributed greatly to the pathogenesis of hepatic fibrosis, including inflammation and fibrosis caused by non-alcoholic fatty liver disease, whereas GR-MD-02 alleviated liver fibrosis by inhibiting galectin 3 and was well tolerated in phase I studies [192]. The gene discussed is LGALS3; the disease is metabolic dysfunction-associated steatotic liver disease.